tradingkey.logo

Kodiak Sciences Q2 net loss misses estimates

ReutersAug 13, 2025 8:11 PM


Overview

  • Kodiak Q2 net loss of $54.3 mln missed analyst expectations

  • Operating income for Q2 beat estimates, driven by clinical study activities

  • Cash position at $104.2 mln, supporting operations into 2026


Result Drivers

  • CLINICAL TRIALS - Increased R&D expenses driven by active Phase 3 studies for tarcocimab, KSI-501, and KSI-101

  • CASH POSITION - Cash reserves of $104.2 mln expected to support operations into 2026

  • MANUFACTURING - Completion of commercial-scale batches at URSUS facility for upcoming BLA submissions


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 EPS

-$1.03

Q2 Net Income

Miss

-$54.31 mln

-$53.70 mln (3 Analysts)

Q2 Operating Income

Beat

-$55.51 mln

-$57.60 mln (4 Analysts)

Q2 Basic EPS

-$1.03

Q2 Operating Expenses

$55.51 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Kodiak Sciences Inc is $3.50, about 143.4% below its August 12 closing price of $8.52

Press Release: ID:nPnbpvHTFa

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI